Caisse DE Depot ET Placement DU Quebec lifted its position in ResMed Inc. (NYSE:RMD) by 3.2% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 22,600 shares of the medical equipment provider’s stock after buying an additional 700 shares during the period. Caisse DE Depot ET Placement DU Quebec’s holdings in ResMed were worth $1,747,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of RMD. NGAM Advisors L.P. grew its position in shares of ResMed by 3.4% in the 2nd quarter. NGAM Advisors L.P. now owns 15,507 shares of the medical equipment provider’s stock worth $1,208,000 after buying an additional 504 shares during the last quarter. Daiwa Securities Group Inc. grew its position in shares of ResMed by 9.1% in the 2nd quarter. Daiwa Securities Group Inc. now owns 4,200 shares of the medical equipment provider’s stock worth $327,000 after buying an additional 350 shares during the last quarter. Global X Management Co. LLC grew its position in shares of ResMed by 9.8% in the 2nd quarter. Global X Management Co. LLC now owns 4,727 shares of the medical equipment provider’s stock worth $368,000 after buying an additional 423 shares during the last quarter. New Mexico Educational Retirement Board purchased a new position in shares of ResMed in the 2nd quarter worth approximately $1,018,000. Finally, Schwab Charles Investment Management Inc. grew its position in shares of ResMed by 1.2% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 446,858 shares of the medical equipment provider’s stock worth $34,797,000 after buying an additional 5,339 shares during the last quarter. 62.02% of the stock is currently owned by hedge funds and other institutional investors.

ResMed Inc. (RMD) traded down $0.60 during mid-day trading on Wednesday, reaching $85.84. 493,200 shares of the company were exchanged, compared to its average volume of 846,984. The firm has a market cap of $12,266.17, a PE ratio of 30.12, a PEG ratio of 1.90 and a beta of 0.78. The company has a quick ratio of 3.86, a current ratio of 4.72 and a debt-to-equity ratio of 0.50. ResMed Inc. has a one year low of $60.13 and a one year high of $87.81.

ResMed (NYSE:RMD) last released its earnings results on Thursday, October 26th. The medical equipment provider reported $0.66 EPS for the quarter, hitting analysts’ consensus estimates of $0.66. ResMed had a net margin of 16.58% and a return on equity of 21.53%. The company had revenue of $523.66 million during the quarter, compared to analysts’ expectations of $506.08 million. During the same period last year, the business earned $0.62 EPS. ResMed’s revenue for the quarter was up 12.5% on a year-over-year basis. sell-side analysts anticipate that ResMed Inc. will post 3.03 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 14th. Shareholders of record on Thursday, November 9th will be paid a dividend of $0.35 per share. This represents a $1.40 annualized dividend and a yield of 1.63%. The ex-dividend date of this dividend is Wednesday, November 8th. ResMed’s payout ratio is 56.68%.

In other ResMed news, insider David Pendarvis sold 6,364 shares of ResMed stock in a transaction that occurred on Tuesday, October 3rd. The shares were sold at an average price of $76.94, for a total transaction of $489,646.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Brett Sandercock sold 1,250 shares of ResMed stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $77.05, for a total transaction of $96,312.50. Following the sale, the chief financial officer now owns 64,691 shares of the company’s stock, valued at $4,984,441.55. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 184,693 shares of company stock valued at $15,149,955. Company insiders own 1.77% of the company’s stock.

A number of research firms recently commented on RMD. Needham & Company LLC reiterated a “sell” rating on shares of ResMed in a research note on Friday, September 8th. Barclays lifted their target price on shares of ResMed from $65.00 to $68.00 and gave the stock an “underweight” rating in a research note on Monday, September 25th. Zacks Investment Research upgraded shares of ResMed from a “sell” rating to a “hold” rating in a research note on Tuesday, October 3rd. Jefferies Group reiterated a “sell” rating and issued a $56.00 target price on shares of ResMed in a research note on Thursday, October 12th. Finally, Northland Securities reiterated a “sell” rating and issued a $55.00 target price on shares of ResMed in a research note on Friday, October 27th. Four investment analysts have rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $68.71.

WARNING: This article was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/12/13/caisse-de-depot-et-placement-du-quebec-has-1-75-million-stake-in-resmed-inc-rmd.html.

ResMed Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Stock Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related stocks with our FREE daily email newsletter.